Detalles de la búsqueda
1.
A value proposition for trough level-based anti-TNFα drug dosing.
Clin Chim Acta
; 489: 89-95, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30521801
2.
Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
Aliment Pharmacol Ther
; 47(3): 356-363, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29205444
3.
Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study.
Clin Rheumatol
; 36(9): 2129-2134, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28593609
4.
Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
Thromb Res
; 139: 128-34, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26916310
5.
Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
J Thromb Haemost
; 12(10): 1636-46, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25142183
Resultados
1 -
5
de 5
1
Próxima >
>>